Krystal Biotech Q3 2025 Earnings Report

Krystal Biotech EPS Results

• Actual EPS: N/A
• Consensus EPS: $1.04
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Krystal Biotech Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $93.72 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Krystal Biotech Announcement Details

• Quarter: Q3 2025
• Date: 11/3/2025
• Time: Before Market Opens
• Conference Call Date: Monday, November 3, 2025
• Conference Call Time: 8:30AM ET

Krystal Biotech (NASDAQ:KRYS) is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition. KB103 has advanced through clinical trials under orphan drug and breakthrough therapy designations granted by the U.S. Food and Drug Administration. In addition to DEB, Krystal Biotech is advancing a second program, KB105, aimed at correcting the genetic defect underlying pseudoxanthoma elasticum. The company maintains an in-house cGMP manufacturing facility to support both development activities and future commercialization efforts.

Since its initial public offering on the Nasdaq in July 2019, Krystal Biotech has expanded its clinical and regulatory footprint, enrolling patients in multiple U.S. and international study sites. The company is led by a management team with deep expertise in gene therapy development and regulatory strategy. With a growing pipeline and a dedicated manufacturing infrastructure, Krystal Biotech is positioned to advance its targeted gene therapies through late-stage development and toward potential approval.